News | June 08, 2009

SCAI Highlights BARI 2D Trial at the American Diabetes Association Scientific Sessions

June 8, 2009 - The Bypass Angioplasty Revascularization Investigation With Diabetes Trial (BARI-2D) is a useful and focused trial that builds on the body of scientific knowledge physicians use to provide the best possible care for diabetic patients with chronic stable angina and to evaluate their treatment options, and the Society for Cardiovascular Angiography and Interventions (SCAI) encourages healthcare providers to apply the findings to patients when appropriate.

BARI-2D specifically applies to patients with carefully controlled diabetes, multivessel but stable coronary artery disease (CAD), and few heart disease symptoms. SCAI said multivessel CAD might be better treated with optimal medical therapy (OMT) plus either percutaneous coronary intervention (PCI) or bypass surgery (CABG).

Since the BARI-2D study enrolled a very small subset of CAD patients with diabetes, SCAI said it looks forward to additional data from the upcoming FREEDOM trial, which may shed more light on revascularization options for this growing patient population.

SCAI said BARI-2D demonstrates intensive surveillance of the diabetes patients works. When the blood sugar levels of diabetic patients are controlled to precise levels, as in clinical trials such as BARI-2D, but not so low as to induce hypoglycemia, the result may achieve strong positive outcomes. The goal is to translate these same types of clinical trial results to a real-world patient scenario, where medical therapy compliance is shown to be a large concern.

"It's important to note that in a real-world setting, patients' blood sugar levels are not so closely monitored to maintain optimal levels as in this study," said Robert Chilton, DO, director of the cardiac catheterization laboratory, South Texas VA Medical Center. "The patients I see with diabetes and heart disease frequently have difficulty complying with a drug regimen that includes upwards of 10 pills per day, often coupled with insulin injection. Not surprisingly, noncompliance can quickly lead to deteriorating health and should be carefully considered for patients who may be candidates for revascularization."

Drug-eluting stents (DES) are the standard of care for diabetic patients undergoing angioplasty and stenting. SCAI said DES are imperative for most diabetic patients who require angioplasty. Many patients enrolled in the revascularization/PCI arm of BARI-2D received bare metal stents because DES were not available in the early years of this trial.

Diabetes patients must be screened for CAD, SCAI said. Many diabetic patients may not exhibit symptoms such as chest pain or shortness of breath. However, patients with type 2 diabetes mellitus and CAD are at high risk for cardiovascular events, including heart attack. According to the American Diabetes Association, diabetes affects nearly 24 million people in the U.S., and more than 65 percent die from heart disease or stroke.

"People with diabetes and the physicians who treat them need to be aware of the crucial importance of cardiovascular disease screening, even in relatively healthy patients with no symptoms," Chilton said. "This study is important because it emphasizes the strong tie between diabetes and heart disease, but does not replace the need for physicians to continue to evaluate the individual needs of each patient."

SCAI said there are limitations to BARI-2D. When evaluating patients for inclusion in the two trial arms of BARI-2D, OMT alone or OMT plus revascularization – all patients received an angiogram to determine the type and severity of blockage(s) in the arteries. SCAI stressed this is an important point to understand – it is these sicker patients, who did not meet the inclusion criteria for the trial based on the diagnostic angiogram, who receive the greatest life-saving benefits from revascularization. Since the patients studied in BARI-2D faced only a small risk of death or heart attack to begin with, it stands to reason that revascularization would not show significant mortality benefits, SCAI said.

Findings from the study are not applicable for every patient population, SCAI said. The BARI-2D trial set out to evaluate whether OMT alone or OMT plus revascularization is better in preventing death and heart attacks in a small, relatively healthy subset of diabetic patients with heart disease. The medical guidelines have never suggested PCI could achieve the life-saving benefits for the "healthier" patients as studied in BARI-2D. The trial's findings, while important, apply only to a narrow group of patients, and should not be generalized across broad groups of cardiovascular patients, SCAI said.

"Physicians should understand the patients in the BARI-2D study are highly selected and represent only a very small slice of diabetes and heart disease patients. More research is needed on the larger diabetic population," said Steven R. Bailey, SCAI president and chief of the division of cardiology at the University of Texas Health Sciences Center at San Antonio. "Unfortunately, the majority of the BARI-2D patients did not receive drug-eluting stents, which have been shown to be superior to bare metal stents for diabetic patients. The standard of care has evolved since BARI-2D was initiated and many of the early patients in the trial did not receive the care we now know to be most effective."

For more information: www.scai.org

Related Content

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Cardiovascular Clinical Studies | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init